Dr. Scott Rowlinson
Chief Scientific Officer
Dr. Scott Rowlinson is a seasoned biotech executive with over 25 years of experience in biologics drug discovery and clinical development, specializing in rare diseases and oncology. He began his career at Eli Lilly, leading antibody target discovery and advancing therapies in immuno-oncology and kidney disease. As a key executive at Aeglea Biotherapeutics, he helped guide the company from inception in 2013 through its 2016 IPO, progressing multiple molecules into clinical trials, with one approved by the EMA and under FDA review. Most recently, as Chief Scientific Officer at Beyond Cancer, he led the development of an innovative gas delivery therapeutic. Dr. Rowlinson excels in pipeline strategy, regulatory submissions, and aligning scientific innovation with business goals. His Six Sigma Black Belt training and leadership skills drive operational efficiency and high-performing teams.